Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Taysha Gene Therapies, Inc. (Nasdaq: TSHA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases, Taysha uses these filings to report on its financial condition, capital-raising activities and material developments in its TSHA-102 Rett syndrome program.
Here, users can review Form 8-K current reports in which Taysha describes material events such as amendments to its at-the-market Sales Agreement for common stock, public follow-on offerings, and key press releases. Recent 8-K filings have incorporated announcements on FDA Breakthrough Therapy designation for TSHA-102, alignment on the REVEAL pivotal trial protocol and statistical analysis plan, and the company’s regaining of full rights to its lead TSHA-102 program.
Investors can also use this page to locate references to quarterly and annual financial results, which are furnished as exhibits to 8-K filings, and to understand how Taysha is funding BLA-enabling manufacturing, REVEAL and ASPIRE clinical trial activities, and general corporate operations. The filings identify TSHA as a Nasdaq-listed issuer with common stock registered under Section 12(b) of the Exchange Act and outline the structure of its equity offering programs.
Stock Titan enhances these regulatory documents with AI-powered summaries that explain the key points of lengthy filings in clear language. Users can quickly see what each 8-K covers, track changes to capital programs and material agreements, and follow how clinical and regulatory milestones for TSHA-102 are reflected in Taysha’s official SEC record. Real-time updates from EDGAR, along with structured views of exhibits and items, help readers navigate the company’s filing history efficiently.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in Taysha Gene Therapies Inc. BlackRock reports beneficial ownership of 17,852,291 shares of Taysha common stock, representing 6.5% of the class as of 12/31/2025. The firm reports sole power to vote 17,558,530 shares and sole power to dispose of 17,852,291 shares, with no shared voting or dispositive power.
The filing explains that these shares are held across certain BlackRock business units, and that various underlying persons have rights to dividends or sale proceeds, but no single person holds more than five percent of the total outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Taysha Gene Therapies.
Taysha Gene Therapies, Inc. reported that its Chief Financial Officer, Kamran Alam, received new equity awards. On January 12, 2026 he was granted 359,000 shares of common stock in the form of restricted stock units, which will vest in four equal annual installments beginning on January 12, 2027, as long as he remains in continuous service.
On the same date, he also received an employee stock option to buy 231,000 shares of common stock at an exercise price of $4.86 per share, with 25% vesting on January 12, 2027 and the rest vesting in 36 equal monthly installments, subject to continued service. After these awards, he beneficially owned 1,546,603 shares of common stock directly and 231,000 stock options directly.
Taysha Gene Therapies, Inc. reported new equity awards to its Chief Executive Officer, Nolan Sean P. On January 12, 2026, he received 1,008,000 shares of common stock in the form of a restricted stock unit (RSU) award at a price of $0 per share, increasing his directly held common stock to 3,086,358 shares. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on his continued service.
On the same date, he was granted an employee stock option for 648,000 shares of common stock with an exercise price of $4.86 per share, expiring on January 12, 2036. Twenty-five percent of the option vests on January 12, 2027, with the remainder vesting in 36 equal monthly installments thereafter, also subject to continued service. Separately, 1,535,545 shares of common stock are held indirectly through Nolan Capital, LLC, where he has shared voting and investment power.
Taysha Gene Therapies president and head of R&D Nagendran Sukumar reported multiple stock transactions on January 12, 2026. He exercised options for 111,324 shares of common stock at an exercise price of
After these moves, he directly held 1,006,439 shares of common stock before receiving an additional 427,000 restricted stock units, which increased his reported common stock holdings to 1,433,439 shares. He also received a new employee stock option for 274,000 shares at an exercise price of
Taysha Gene Therapies insider Sukumar Nagendran has filed a Form 144 notice to sell 200,000 shares of common stock. The planned sale has an aggregate market value of $996,000, with trades expected around 01/12/2026 through Jefferies LLC on the Nasdaq market. The filing notes 273,920,000 shares of common stock outstanding.
The 200,000 shares were acquired via vested stock option grants from Taysha Gene Therapies, Inc. on 05/31/2023 (111,324 shares) and 01/02/2024 (88,676 shares. In the past three months, Nagendran has already sold 110,125 shares on 11/28/2025 for gross proceeds of $522,774.39 and 260,047 shares on 12/01/2025 for gross proceeds of $1,172,837.97.
Taysha Gene Therapies (TSHA) amended its at‑the‑market equity program, increasing the aggregate offering amount under its Sales Agreement to $212 million as of November 4, 2025, and terminating Leerink Partners as a sales agent.
Under the amended arrangement, Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC remain as sales agents. Sales, if any, may be made from time to time as an “at the market offering” on the Nasdaq Global Select Market or other existing trading markets. The company is not obligated to sell shares.
As context, the company had previously sold common stock with an aggregate offering price of approximately $12 million under the program as of September 30, 2025.
Taysha Gene Therapies reported Q3 2025 results showing higher liquidity and ongoing operating losses. Cash and cash equivalents were $297.3 million, up from $139.0 million at year-end, and total assets reached $316.6 million. The company recorded a Q3 net loss of $32.7 million (basic and diluted net loss per share $0.09) on operating expenses of $34.0 million, driven by research and development of $25.7 million and general and administrative of $8.3 million. Net cash used in operating activities for the first nine months was $66.4 million.
Liquidity improved through a May 2025 underwritten offering that generated $215.6 million in net proceeds and an August 2025 $50.0 million Tranche A term loan with Trinity; the 2023 Trinity loan was repaid at $40.6 million. Deferred revenue of $5.5 million tied to the Astellas Rett option is set to be recognized in Q4 2025 after the option expired unexercised, returning unencumbered rights to TSHA-102. As of November 4, 2025, common shares outstanding were 273,919,373.
Taysha Gene Therapies (TSHA) filed a current report stating it issued a press release titled “Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome.”
The press release, dated October 16, 2025, is furnished as Exhibit 99.1 and incorporated by reference. TSHA-102 is described as the company’s lead program under clinical evaluation for Rett syndrome. No additional terms or financial details are included in this excerpt.
Taysha Gene Therapies, Inc. filed a current report to let investors know it has issued a new press release about its lead Rett syndrome gene therapy candidate, TSHA-102. The press release, dated October 9, 2025, presents a supplemental data analysis from Part A of the REVEAL Phase 1/2 clinical trials in Rett syndrome, and the data were shared at the 54th Child Neurology Society Annual Meeting.
The full text of this press release is included as Exhibit 99.1 to the report and is incorporated by reference, meaning detailed clinical and scientific information is contained in that exhibit rather than in the body of the report itself.
Taysha Gene Therapies, Inc. reported that it issued a press release titled “Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome.” The company states that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for TSHA-102, its investigational therapy for Rett syndrome, and that it has received a positive regulatory update on this program. The full details are provided in the press release attached as Exhibit 99.1.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
